e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Gráinne d'Ancona, Joanne Kavanagh, Cris Roxas, Linda Green, Mariana Fernandes, Louise Thomson, Jaideep Dhariwal, Alexandra M. Nanzer, David J. Jackson, Brian D. Kent
Source:
Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019
Journal Issue:
May
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Gráinne d'Ancona, Joanne Kavanagh, Cris Roxas, Linda Green, Mariana Fernandes, Louise Thomson, Jaideep Dhariwal, Alexandra M. Nanzer, David J. Jackson, Brian D. Kent. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Severe asthma outcomes over two years of therapy with mepolizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018
Year: 2018
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
The efficacy of omalizumab in severe in asthma after treatment withdrawal
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma
Source: Annual Congress 2010 - Allergy and risk factors in paediatrics
Year: 2010
Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort
Source: International Congress 2018 – Clinical markers of asthma
Year: 2018
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
Source: Breathe 2010; 6: 365
Year: 2010
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Year: 2020
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept